1. Academic Validation
  2. Structure of the active Gi-coupled human lysophosphatidic acid receptor 1 complexed with a potent agonist

Structure of the active Gi-coupled human lysophosphatidic acid receptor 1 complexed with a potent agonist

  • Nat Commun. 2022 Sep 15;13(1):5417. doi: 10.1038/s41467-022-33121-2.
Hiroaki Akasaka 1 Tatsuki Tanaka 1 Fumiya K Sano 1 Yuma Matsuzaki 1 Wataru Shihoya 2 Osamu Nureki 3
Affiliations

Affiliations

  • 1 Department of Biological Sciences, Graduate School of Science, The University of Tokyo, Bunkyo, Tokyo, 113-0033, Japan.
  • 2 Department of Biological Sciences, Graduate School of Science, The University of Tokyo, Bunkyo, Tokyo, 113-0033, Japan. [email protected].
  • 3 Department of Biological Sciences, Graduate School of Science, The University of Tokyo, Bunkyo, Tokyo, 113-0033, Japan. [email protected].
Abstract

Lysophosphatidic acid receptor 1 (LPA1) is one of the six G protein-coupled receptors activated by the bioactive lipid, lysophosphatidic acid (LPA). LPA1 is a drug target for various diseases, including Cancer, inflammation, and neuropathic pain. Notably, LPA1 agonists have potential therapeutic value for obesity and urinary incontinence. Here, we report a cryo-electron microscopy structure of the active human LPA1-Gi complex bound to ONO-0740556, an LPA analog with more potent activity against LPA1. Our structure elucidated the details of the agonist binding mode and receptor activation mechanism mediated by rearrangements of transmembrane segment 7 and the central hydrophobic core. A structural comparison of LPA1 and other phylogenetically-related lipid-sensing GPCRs identified the structural determinants for lipid preference of LPA1. Moreover, we characterized the structural polymorphisms at the receptor-G-protein interface, which potentially reflect the G-protein dissociation process. Our study provides insights into the detailed mechanism of LPA1 binding to agonists and paves the way toward the design of drug-like agonists targeting LPA1.

Figures
Products